GeminIQ Website Logo

Viewing ADCT free

Subscribe for full history, 90+ metrics, screener, watchlist...

ADC Therapeutics SA

ADCT

Companies in Pharmaceutical Preparations

Subscribe to unlock 17+ years of data

Financial Statements

Values in Millions ($)
2026-03-31
2025-12-31
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial
Subscriber-only column
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value
231261235265195251274300234279
Accounts And Other Receivables Net Current
31292326322024232325
Inventory Net
54181817216151616
Prepaid Expense And Other Assets Current
66657819171710
Other Assets Current
466679---6
Assets Current
277306287319258291333355290336
Inventory Noncurrent
1214---16----
Property Plant And Equipment Net
-000556566
Operating Lease Right Of Use Asset
1111889101011
Equity Method Investments
-----00012
Deferred Income Tax Assets Net
---------0
Other Assets Noncurrent
1111111111
Assets
291323290322273322349372308355
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current
59810161814111416
Accrued Liabilities Current
58585455426253474952
Operating Lease Liability Current
---------1
Long Term Debt Current
53---0----
Liabilities Current
68706265588068586368
Secured Long Term Debt
111112115114114114114114113113
Warrants And Rights Outstanding
19---------
Operating Lease Liability Noncurrent
111188991010
Other Liabilities Noncurrent
5397428779
Liabilities
508509528521511525521503502503
Stockholders Equity Inclu…
Common Stock Value
11111010888877
Additional Paid In Capital
1,4421,4401,3821,3801,2871,2841,2821,2791,1811,181
Treasury Stock Value
-0-0-0-0-0-0-0-0-1-1
Accumulated Other Comprehensive Income Loss Net Of…
-1-1-1-0-1-10-0-0-0
Retained Earnings Accumulated Deficit
-1,669-1,636-1,630-1,589-1,532-1,493-1,463-1,419-1,382-1,335
Stockholders Equity
-216-186-238-199-238-203-172-132-194-148
Liabilities And Stockholders Equity
291323290322273322349372308355
Common Stock Par Or Stated Value Per Share
0.080.080.080.080.080.080.080.080.080.08
Common Stock Shares Issued
13012811511510210299998989
Shares Outstanding
127126113112999997968382
Treasury Stock Common Shares
3333333367

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Custom Table

0/5
Search a metric to start building a table

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Interactive Financial Visualizations

0/1
Search a metric to start building a visual

Subscribe to unlock 17+ years of data

Earnings Market Reaction

Fiscal Year
Q1 1 Month
Q1 2 Month
Q1 3 Month
Q2 1 Month
Q2 2 Month
Q2 3 Month
Q3 1 Month
Q3 2 Month
Q3 3 Month
Q4 1 Month
Q4 2 Month
Q4 3 Month
2026-7.61%-72.28%-68.75%---------
2025102.76%57.46%48.62%20.41%38.78%51.70%-21.85%-16.39%-14.25%-21.25%-20.21%-29.17%
2024-22.92%-28.99%-18.43%-0.68%5.48%1.03%-17.41%-30.72%-39.59%-20.39%24.34%135.53%
2023---------28.21%25.64%-12.05%

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Performance and Valuation Metrics

Metrics
2026-03-31
2025-12-31
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial
Subscriber-only column
Liquidity Ratios
Current Ratio
4.09
4.37
4.63
4.93
4.46
3.62
4.92
6.17
4.61
4.97
Quick Ratio
3.94
4.23
4.24
4.59
4.04
3.49
4.41
5.60
4.09
4.58
Working Capital
209.14M
236.17M
225.11M
254.16M
200.20M
210.79M
265.33M
297.73M
227.22M
268.62M
Leverage & Debt
Debt to Equity
-2.35
-2.74
-2.22
-2.61
-2.14
-2.59
-3.03
-3.82
-2.58
-3.39
Interest Coverage TTM
-2.29
-2.35
-2.16
-2.24
-2.01
-2.08
-2.56
-
-
-
Debt Ratio
1.74
1.58
1.82
1.62
1.87
1.63
1.49
1.35
1.63
1.42
Efficiency & Turnover
Asset Turnover TTM
0.30
0.25
0.21
0.20
0.24
0.21
0.15
-
-
-
Per Share Metrics
Diluted EPS TTM
-0.89
-1.12
-1.22
-1.49
-1.40
-1.62
-1.21
-
-
-
Free Cash Flow Per Share TTM
-0.74
-1.11
-0.97
-1.12
-1.27
-1.28
-0.98
-
-
-
Dividend Per Share TTM
0.00
0.00
0.00
0.00
0.00
0.00
0.00
-
-
-
Margin Metrics
Operating Profit Margin TTM
-139.47%
-149.34%
-199.59%
-198.43%
-178.81%
-184.44%
-182.13%
-
-
-
Net Profit Margin TTM
-161.54%
-175.31%
-244.96%
-239.82%
-213.49%
-222.83%
-235.72%
-
-
-
Growth Metrics
Net Revenue Growth (1Y)
20.82%
14.85%
26.37%
-
-
-
-
-
-
-
Net Income Growth (1Y)
-8.58%
-9.64%
31.33%
-
-
-
-
-
-
-
EPS Growth (1Y)
-36.42%
-30.91%
0.89%
-
-
-
-
-
-
-
Valuation Metrics
P/E TTM
-4.22
-3.14
-3.27
-1.79
-1.01
-1.22
-2.60
-
-
-
P/B TTM
-2.67
-2.41
-2.29
-1.53
-0.63
-0.95
-1.92
-2.30
-1.91
-0.91
P/S TTM
6.82
5.51
8.01
4.30
2.15
2.73
6.12
-
-
-
Market Cap
578.03M
448.55M
545.79M
304.83M
151.16M
193.35M
330.20M
302.38M
370.66M
135.64M
Enterprise Value
462.70M
302.66M
426.25M
154.75M
70.28M
56.11M
170.12M
115.94M
249.61M
-30.23M
Calculated Values
Free Cash Flow TTM
-114.58M
-141.44M
-132.26M
-127.89M
-136.67M
-124.70M
-102.76M
-
-
-
Net Debt
-115.33M
-145.89M
-119.53M
-150.09M
-80.88M
-137.24M
-160.08M
-186.45M
-121.05M
-165.87M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of data

Insider Transactions

2026-04-02Sale
Owner: Redco, Ii Master Fund, L.…
Title: -
Shares: 2,529,491
Price/Share: $3.28
Value: $8,296,730.48
Shares Owned: 10,265,297
Relationship: TenPercentOwner
Ownership: Direct
2024-12-11Purchase
Owner: Green, Jeremy, Redco Ii M…
Title: -
Shares: 100,000
Price/Share: $3.04
Value: $304,000.00
Shares Owned: 13,145,712
Relationship: TenPercentOwner
Ownership: Direct
2024-12-04Sale
Owner: Redco, Ii Master Fund, L.…
Title: -
Shares: 25,352
Price/Share: $2.07
Value: $52,478.64
Shares Owned: 15,566,731
Relationship: TenPercentOwner
Ownership: Indirect
2024-07-01Purchase
Owner: Redco, Ii Master Fund, L.…
Title: -
Shares: 400,000
Price/Share: $2.81
Value: $1,124,000.00
Shares Owned: 12,995,040
Relationship: TenPercentOwner
Ownership: Direct
2024-06-17Sale
Owner: Monges, Viviane
Title: -
Shares: 1,437
Price/Share: $2.89
Value: $4,152.93
Shares Owned: 106,627
Relationship: Director
Ownership: Direct

Subscribe to unlock 17+ years of data

Institutional Ownership

No data available for chart
2026-03-31
53.52%
Inst. Shares: 82,495,304
Shares Outstanding: 154,142,347
2025-12-31
64.71%
Inst. Shares: 82,222,336
Shares Outstanding: 127,067,540
2025-09-30
49.47%
Inst. Shares: 67,496,287
Shares Outstanding: 136,446,534
2025-06-30
59.77%
Inst. Shares: 67,979,230
Shares Outstanding: 113,743,358
2025-03-31
50.95%
Inst. Shares: 54,619,923
Shares Outstanding: 107,202,374

ADC Therapeutics SA (ADCT) — SEC Financial Statements & Analysis

ADC Therapeutics SA (ADCT) is a pharmaceutical preparations company, incorporated in V8. ADC Therapeutics SA trades on NYSE as: ADCT. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), ADC Therapeutics SA reported a 20.82% year-over-year revenue growth, a Debt-to-Equity ratio of -2.35x, a Price-to-Sales (P/S) ratio of 6.82x (TTM), a Price-to-Book (P/B) ratio of -2.67 (TTM), at a market cap of $578.03M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y
20.82%
Debt To Equity
-2.35x
P/S TTM
6.82x
P/B TTM
-2.67
Market Cap
$578.03M

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is ADC Therapeutics SA in?

ADC Therapeutics SA (ADCT) operates in the Pharmaceutical Preparations industry.

What is ADCT's market cap?

ADC Therapeutics SA (ADCT) has a market capitalization of $578.03M as of 2026-03-31.

What exchange does ADCT trade on?

ADC Therapeutics SA (ADCT) trades on the NYSE.

Where is ADC Therapeutics SA incorporated?

ADC Therapeutics SA is incorporated in Switzerland.

Research Faster.
Invest Smarter.

ADC Therapeutics SA (ADCT) financial data sourced directly from SEC EDGAR filings — including the latest 10-K annual report, 10-Q quarterly filings, insider transactions (SEC Form 4), institutional ownership (SEC Form 13F), Earning Marker Reaction Heat Map and 90+ calculated financial metrics like Price to Earnings Ratio (P/E), Return on Equity (ROE), Debt to Equity (D/E), Free Cash Flow Per Share (FCF/S), and Return on Invested Capital (ROIC). Unlike platforms that rely on third-party data aggregators, GeminIQ parses raw SEC filings directly — delivering institutional-grade accuracy at a fraction of the cost of Bloomberg Terminal or S&P Capital IQ.